Similarly to FVC decline, no between-group difference was observed in progression-free survival, that was nearly two years, supporting the beneficial effect of antifibrotic treatment in IPF, irrespective of MUC5B genotype [28–30]. Here, MUC5B is linked to idiopathic pulmonary fibrosis.